ClinicalTrials.gov
public full text
Public Domain
Anti-GPC3 CAR T for Treating Patients With Advanced HCC
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307#913717
- A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)#994885
- A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)#261517
- A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer#842478
- Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma#917108
Record · ID 1259283
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive